Asking for clarification about TheStreet.Com's position on Radient Pharmaceuticals [updated] Print E-mail
By Staff and Wire Reports   
Thursday, 24 March 2011 15:03

street.comInvestors flood email boxes at BioMedReports and Radient Pharmaceuticals (Amex:RPC) after TheStreet.Com's Adam Feuerstein calls company's investors "Radient Retards."

Did TheStreet.Com make up the facts against Radient Pharmaceuticals?

M.E. Garza of BioMedReports has sent an e-mail to management at TheStreet.Com to ask for clarification as to their position on the company, after it appeared that Mr. Feuerstein re-iterated his feelings about Radient investors via official company email.

Attached is a copy of the email exchange.

Update: The shareholder who had asked Mr. Feuerstein for an apology on behalf of all Radient shareholders got this response:

 

 

Shares of the company are trading up over 5% since the comments.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter